English | Español
Press release submission | Oct 8, 2021

Positive Data from Nanoscope's Phase 1/2a Trial of Gene Therapy to Restore Vision in Patients Blinded by Retinitis Pigmentosa to be Featured at 2021 American Society of Retina Specialists Meeting

Press release submission | Oct 8, 2021

Janssen Submits Application Seeking U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis

Press release submission | Oct 7, 2021

Late-breaking Data From PROMISE I Study On LimFlow System Confirm Excellent Sustained Outcomes In Patients With No-option Chronic Limb-threatening Ischemia
Press release submission | Oct 7, 2021

Khiron presents its first research study with 1,400 patients

Press release submission | Oct 2, 2021

Alzinova receives approval to start the first clinical study with the oligomer-specific ALZ-101 vaccine in patients with Alzheimer's disease

Press release submission | Oct 1, 2021

Banty's Dr. Richard Tytus Discusses How to Get Patients to Have More Online Doctor's Appointments
Press release submission | Oct 1, 2021

CNS Pharmaceuticals Doses First Group of Patients with Berubicin, an FDA-Designated Fast Track Drug Candidate, in the Potentially Pivotal Study for the Treatment of Glioblastoma Multiforme (GBM)
Press release submission | Oct 1, 2021

NCCN Publishes New Guide to Improving Knowledge and Quality of Life for Small Cell Lung Cancer Patients

Trending
+ Pharmaceuticals
Patient Daily | Jun 18, 2025

ENT specialist on acid reflux: ‘You actually have a structural issue that may predispose you to sinusitis’
+ Pharmaceuticals
Patient Daily | Jun 16, 2025

American Consumer Institute questions hospital use of 340B Drug Pricing Program
+ Pharmaceuticals
Patient Daily | Jun 13, 2025

Data scientist: ‘340B sales growth was 115.5% higher than the growth of non-340B sales in 2023’
+ Pharmaceuticals
Patient Daily | Jun 19, 2025

Patients Come First spokesperson on 340B reform: ‘Americans deserve a system that prioritizes patients first, not pharmacy middlemen’